The highly reducing and immunosuppressive environment within solid tumors limits the application of ferroptosis and immunotherapy in clinical treatment. Elevated SLC7A11 transporter expression can strengthen tumor cells’ resistance to ferroptosis, but induce disulfidptosis under glucose starvation conditions. Here, using the ferroptosis resistance mechanism of tumor cells, we created a multifunctional nanoparticle (BZTFH) to induce disulfidptosis and accelerate ferroptosis, eventually causing immunogenic cell death (ICD) of tumor cells for synergistic cancer immunotherapy. After cellular internalization, the metal polyphenol network releases iron ions under acidic conditions, and then ZnO2 is degraded into Zn2+ and H2O2. The iron ions and H2O2 generate a sustained and powerful ROS storm through the Fenton reaction. Consequently, ferroptosis resistance is activated. Finally, the released glucose transporter inhibitor depletes the intracellular NADPH pool, and accumulates a large amount of intracellular disulfide molecules, thereby inducing cell disulfidptosis. The destruction of the reducing environment, along with the occurrence of disulfidptosis and ferroptosis, promotes the ICD effect. Simultaneously, Zn2+ causes STING activation, which in turn stimulate particular T cell responses, thereby reducing immunosuppression within the tumor microenvironment (TME). In short, we have successfully integrated ferroptosis and disulfidptosis for immunotherapy for the first time, presenting a potential therapeutic strategy for clinical application.
Read full abstract